Edulis provides a bioresorbable, endoscopically implanted drug delivery system that releases small‑molecule therapeutics directly at the target site in the gastrointestinal tract for up to 12 months. The ultra‑thin polymer implant is placed during a routine outpatient endoscopy using a custom insertion tool, offering controlled, maintenance‑free dosing, higher local bioavailability, and reduced systemic side effects for chronic GI conditions.
Funding
$200K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with chronic gastrointestinal conditions often require frequent medication dosing, which can lead to poor adherence, systemic side effects, and high long‑term costs. Current delivery methods such as oral pills, injections, or infusions provide limited local bioavailability and may require repeated clinical visits.
Solution
Edulis offers a bioresorbable, endoscopically implanted drug delivery system that releases small‑molecule therapeutics directly at the target site in the gastrointestinal tract. The implant, thinner than a grain of rice, is placed during a routine outpatient endoscopy using a custom insertion tool, requiring minimal training for GI clinicians. Its polymer matrix provides controlled, sustained release for up to 12 months, eliminating the need for daily dosing, injections, or infusions. By delivering medication locally, the system increases bioavailability, reduces systemic exposure, and lowers the risk of side effects. The fully resorbable design removes the need for surgical removal, simplifying long‑term management and reducing overall patient costs.
Target Audience
Primary customers are gastroenterology clinics and hospital GI departments treating chronic conditions such as inflammatory bowel disease, chronic pain, and other gastrointestinal disorders that benefit from localized, long‑acting therapy.
Features
- Bioresorbable polymer implant thinner than a grain of rice for minimally invasive endoscopic placement
- Controlled, zero‑order release kinetics delivering medication for up to 12 months without maintenance
- High local bioavailability with reduced systemic side effects compared to oral formulations
- Custom‑designed insertion tool enabling deployment by any GI clinician with limited additional training
- Compatibility with a broad range of small‑molecule drugs, allowing extension of existing therapeutics to new indications
- Fully resorbable matrix eliminates the need for explant surgery after drug depletion